Kringle Pharma (TSE:4884) Ending Cash Position: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
47 GF Score
Price 円423.00
GF Value 円475.69
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Ending Cash Position?

Kringle Pharma TSE:4884 -0.47% 47 Ending Cash Position is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 47/100 and a GF Value™ of 円475.69 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Kringle Pharma's Ending Cash Position for the quarter that ended in Mar. 2026 was 円0.0 Mil.

Kringle Pharma's annual Ending Cash Position increased from Sep. 2023 (円1,761.2 Mil) to Sep. 2024 (円1,816.9 Mil) but then declined from Sep. 2024 (円1,816.9 Mil) to Sep. 2025 (円991.3 Mil).

Kringle Pharma Ending Cash Position Related Terms

Kringle Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Ending Cash Position Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Ending Cash Position
Get a 7-Day Free Trial 2,137.52 2,502.05 1,761.24 1,816.94 991.30

Kringle Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4884
47GF Score
Kringle Pharma Inc TSE:4884
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kringle Pharma's Ending Cash Position for the fiscal year that ended in Sep. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1816.943+-825.647
=991.3

Kringle Pharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0.0 Mil mean?
Kringle Pharma (TSE:4884) has a Ending Cash Position of 円0.0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Ending Cash Position too high?
Kringle Pharma's current Ending Cash Position is 円0.0 Mil. Overall, Kringle Pharma has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Ending Cash Position compare to VRTX and REGN?
Kringle Pharma's Ending Cash Position of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Ending Cash Position is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Modestly Undervalued. The stock's GF Value™ is 円475.69, compared to a current price of 円423.00 — trading 11.1% below its estimated fair value. The current Ending Cash Position is 円0.0 Mil. Kringle Pharma's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Ending Cash Position is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円423.00 is trading 11.1% below its estimated GF Value™ of 円475.69. GuruFocus considers Kringle Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4884:

  • Ending Cash Position: 円0.0 Mil
  • GF Value™: 円475.69 vs. price of 円423.00 (11.1% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
47GF Score

Get the complete analysis for TSE:4884

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円423.00
Price
円475.69
GF Value